Postgraduate Program in Pathology, Universidade Federal de Ciências da Saúde de Porto Alegre, Porto Alegre, RS, Brazil.
Faculty of Medicine, Universidade Federal do Pampa, Uruguaiana, RS, Brazil.
An Bras Dermatol. 2022 Jan-Feb;97(1):37-44. doi: 10.1016/j.abd.2021.05.009. Epub 2021 Nov 27.
Infantile hemangiomas (IH) occur in approximately 4% to 10% of the pediatric population. The identification of clinical subtypes and conditions that indicate increased risk for complications is essential for therapeutic success.
To identify risk factors for complications, recurrence and unaesthetic sequelae.
Retrospective cohort of patients with infantile hemangiomas undergoing follow-up at the Dermatology Service of Universidade Federal de Ciências da Saúde de Porto Alegre, between 2006 and 2018.
190 patients were included; 24% had some type of complication, ulceration being the most frequent, and 86% required treatment. On correlation, ulceration was statistically related to mixed IH (p = 0.004), segmental IH (p < 0.01) and location in the gluteal region (p = 0.001). The mean time of treatment with propranolol was 12.7 months. Patients with PHACES syndrome and segmental infantile hemangioma required longer treatment (p < 0.001 and p = 0.0407, respectively), as well as those who started treatment after five months of life (p < 0.0001). Recurrence occurred in 16.6% of the treated patients, all-female; 94% were located on the head and neck (mainly on the upper eyelid, cyrano, S3 segment, and with parotid involvement); 61% and 38.8% were of the mixed and deep subtypes, respectively. Approximately 1/3 of the patients had some unaesthetic sequelae.
As this is a retrospective study, data and photos of some patients were lost.
Mixed and segmental hemangiomas are risk factors for ulceration and sequelae. Recurrence occurs more often in females and segmental hemangiomas. Segmental infantile hemangioma and PHACES syndrome require a longer time of treatment. Specific protocols are required for infantile hemangiomas with a high risk of recurrence.
婴儿血管瘤(IH)在儿科人群中的发病率约为 4%至 10%。识别临床亚型和预示并发症风险增加的情况对于治疗成功至关重要。
确定并发症、复发和不美观后遗症的危险因素。
回顾性队列研究了 2006 年至 2018 年期间在阿雷格里港联邦大学健康科学皮肤科接受随访的患有婴儿血管瘤的患者。
共纳入 190 例患者;24%存在某种类型的并发症,其中溃疡最常见,86%需要治疗。相关性分析显示,溃疡与混合性 IH(p=0.004)、节段性 IH(p<0.01)和臀部位置(p=0.001)有统计学关系。普萘洛尔治疗的平均时间为 12.7 个月。患有 PHACES 综合征和节段性婴儿血管瘤的患者需要更长的治疗时间(p<0.001 和 p=0.0407),以及在 5 个月后开始治疗的患者(p<0.0001)。接受治疗的患者中有 16.6%(均为女性)出现复发,所有患者均位于头颈部(主要在上眼睑、Cyrano、S3 节段,伴有腮腺受累);94%;94%为混合性和深部亚型,分别为 61%和 38.8%。大约 1/3 的患者存在一些不美观的后遗症。
由于这是一项回顾性研究,一些患者的数据和照片丢失。
混合性和节段性血管瘤是溃疡和后遗症的危险因素。复发更多发生在女性和节段性血管瘤中。节段性婴儿血管瘤和 PHACES 综合征需要更长的治疗时间。对于复发风险高的婴儿血管瘤,需要制定特定的方案。